Jump to navigation Jump to search

CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass470.603 g/mol

WikiDoc Resources for Bazedoxifene


Most recent articles on Bazedoxifene

Most cited articles on Bazedoxifene

Review articles on Bazedoxifene

Articles on Bazedoxifene in N Eng J Med, Lancet, BMJ


Powerpoint slides on Bazedoxifene

Images of Bazedoxifene

Photos of Bazedoxifene

Podcasts & MP3s on Bazedoxifene

Videos on Bazedoxifene

Evidence Based Medicine

Cochrane Collaboration on Bazedoxifene

Bandolier on Bazedoxifene

TRIP on Bazedoxifene

Clinical Trials

Ongoing Trials on Bazedoxifene at Clinical

Trial results on Bazedoxifene

Clinical Trials on Bazedoxifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bazedoxifene

NICE Guidance on Bazedoxifene


FDA on Bazedoxifene

CDC on Bazedoxifene


Books on Bazedoxifene


Bazedoxifene in the news

Be alerted to news on Bazedoxifene

News trends on Bazedoxifene


Blogs on Bazedoxifene


Definitions of Bazedoxifene

Patient Resources / Community

Patient resources on Bazedoxifene

Discussion groups on Bazedoxifene

Patient Handouts on Bazedoxifene

Directions to Hospitals Treating Bazedoxifene

Risk calculators and risk factors for Bazedoxifene

Healthcare Provider Resources

Symptoms of Bazedoxifene

Causes & Risk Factors for Bazedoxifene

Diagnostic studies for Bazedoxifene

Treatment of Bazedoxifene

Continuing Medical Education (CME)

CME Programs on Bazedoxifene


Bazedoxifene en Espanol

Bazedoxifene en Francais


Bazedoxifene in the Marketplace

Patents on Bazedoxifene

Experimental / Informatics

List of terms related to Bazedoxifene

Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Wyeth under the tradename Viviant™. Bazedoxifene's combination with conjugated estrogens, Aprela™, is currently undergoing Phase III studies.

Wyeth received an approvable letter for Bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth is working with the FDA to resolve these issues, and expects an FDA action date at year end.

Template:Sex hormones


BROWN, EMILY. "Wyeth's osteoporosis drug cut risk of new fractures". Retrieved 2007-09-28. "Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis". Retrieved 2007-09-28.

Template:WikiDoc Sources